Innate Pharma (IPHA) — Cash Flow Reinvestment Rate
Innate Pharma (IPHA) has a Cash Flow Reinvestment Rate of 0.09x as of June 2024, reinvesting $283.00K (capex $283.00K ) from operating cash flow of $3.04 Million. Check Innate Pharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Innate Pharma Cash Flow Reinvestment Rate (2006–2019)
Historical reinvestment intensity for Innate Pharma across 4 annual periods. Explore long-term investment intensity of Innate Pharma to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Innate Pharma (2006–2019)
Year-by-year capital reinvestment analysis for Innate Pharma. For live market cap and broader valuation context, see IPHA stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 3.65x | $127.52 Million | $34.92 Million | $65.40 Million | ▲ +469.8% |
| 2015 | 0.64x | $133.24 Million | $207.91 Million | $7.40 Million | ▲ +2484.4% |
| 2011 | 0.02x | $322.00K | $12.99 Million | $322.00K | ▼ -98.8% |
| 2006 | 2.09x | $752.00K | $360.00K | $752.00K | — |